BBB penetration drug delivery platform is needed to treat brain diseases such as Alzheimer’s, Parkinson’s, and brain tumors
‘NIPEP-TPP-BBB Shuttle (hereinafter referred to as BBB Shuttle)’, a cerebrovascular barrier (BBB) penetrating delivery system that Nyvec, a peptide fusion bio company, successfully developed, showed a high transmittance of 9% of the administered dose. It was announced on the 27th that the mechanism was completed.
In particular, since joint research with global pharmaceutical companies and out-licensing cannot be done without identifying the mechanism, discussions with global pharmaceutical companies are intensifying with this mechanism identification.
The company explains that this is because NIPEP-TPP, which is designed with a targeting function that delivers the drug effect precisely to the desired area, is applied.
Based on this, as a result of conducting research on mechanism identification with global pharmaceutical companies, this time, it confirmed the clear mechanism and high BBB permeability of 9%.
The blood-brain barrier (BBB) is a biological barrier that selectively passes nutrients needed from the blood to maintain the function of brain neurons and regulate the microenvironment in brain tissue, and restricts dangerous substances. Substances with very small molecular sizes can pass through the BBB relatively easily, but substances with large molecular weights such as antibodies, proteins, and genes that must act inside the brain or low-molecular drugs used for neurological diseases are difficult to penetrate the BBB.
The BBB acts as a primary defense barrier that prevents the intrusion of foreign substances, but it also acts as a kind of obstacle because the therapeutic agent cannot penetrate. Therefore, in order to treat brain diseases such as Alzheimer’s, Parkinson’s, and brain tumors, a drug delivery platform that can penetrate the BBB is needed.
An official from Nyvec said, “For the treatment of brain diseases, not only BBB penetration but also a high level of drug delivery ratio is the key. Nyvek has confirmed a high permeability of 9%.” “Nyvec has structurally designed a peptide targeting a receptor that is highly expressed in cerebrovascular endothelial cells and a peptide with a cell penetrating function to develop the BBB shuttle. It was confirmed that the distribution concentration in the normal rat brain tissue was three times higher than when the peptide was applied.”
He continued, “BBB Shuttle has already been steadily conducting research to identify mechanisms with global pharmaceutical companies, and has confirmed its excellent BBB penetrating function not only in antibodies but also in gene siRNA and protein. We have high expectations for technology transfer through joint R&D and multi-faceted cooperation in the future.”
.
